Skip to main content

Table 3 Efficacy of lenvatinib in patients with uHCC

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

 

LEN monotherapy

(n = 39)

LEN combination (n = 72)

LEN + PD1 (n = 30)

LEN + HAIF/TACE (n = 24)

LEN + PD1 + HAIF/TACE (n = 16)

CR

0

2/3%

1/3%

0

0

PR

6/15%

19/26%

10/33%

7/29%

2/13%

SD

21/54%

42/58%

12/40%

17/71%

12/75%

ORR

15%

29%

36%

29%

13%

DCR

69%

87%

76%

100%

88%

  1. Data are presented as n/%
  2. LEN, lenvatinib; PD-1, programmed cell death protein-1 targeted immunotherapy; HAIF, hepatic arterial infusion with drug filtration; TACE, transcatheter arterial chemoembolization; CR, complete response; ORR, objective response rate; DCR, disease control rate; PR, partial response; SD, stable disease